Agnieszka Orzińska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agnieszka Orzińska has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Katarzyna Guz
Department of Hematological and Transfusion Immunology Institute of Hematology and Transfusion Medicine Warsaw Poland
25 shared publications - Ewa Brojer
Zakład Immunologii Hematologicznej i Transfuzjologicznej Instytutu Hematologii i Transfuzjologii w Warszawie
22 shared publications - Małgorzata Uhrynowska
Department of Immunology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
7 shared publications - Marzena Dębska
2nd Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland
6 shared publications Bogumiła Michalewska
Department of Immunohematology and Immunology for Transfusion Medicine; Institute of Hematology and Transfusion Medicine in Warsaw
5 shared publicationsKatarzyna Guz
Immunohematology Institute of Hematology and Transfusion Medicine Warsaw Poland
4 shared publications
Latest Publications
- 16 January 2026
- Published by Wiley in Transfusion
- Vol. 66 (4) , 814-827
HPA ‐1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT
Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) caused by antibodies to human platelet antigen (HPA)‐1a in white HPA‐1a‐negative mothers is the most frequent cause of intracranial hemorrhage (ICH) in otherwise healthy newborns. Aims: To investigate the natural history of FNAIT and establish a biobank from HPA‐1a‐negative alloimmunized and nonimmunized pregnancies. Methods: A total of 24,259 pregnant women were recruited to the study during 2013–2017 and 24,236 were screened for HPA‐1a. Anti‐HPA‐1a antibodies were tested by Monoclonal Antibody Immobilization of Platelet Antigens (MAIPA) and some samples (MAIPA‐negative), with Luminex bead‐based immunoassay (PAKLx) if the neonate had thrombocytopenia and/or ICH. HPA‐1 genotyping of fathers, fetuses (from maternal plasma), and newborns was performed. Biological material was stored in biobanks in Norway and Poland. Results: Among 583/24,236 (2.4%) HPA‐1a‐negative women, samples were obtained from 529, of which 513 were examined during pregnancy. Anti‐HPA‐1a antibodies were detected in 48/529 (9.1%) women; whereof 34/513 (6.6%) during pregnancy, either by prospective MAIPA ( n = 27) or in retrospect by PAKLx in MAIPA‐negatives ( n = 7). FNAIT was diagnosed in 11/34 (32%) neonates from alloimmunized pregnancies: in 6/11 cases by prospective MAIPA and in 5/11 by retrospective PAKLx. There were no neonates with FNAIT‐associated ICH delivered by MAIPA‐positive women, but 3 ICH/severe thrombocytopenia cases were diagnosed by PAKLx. Among nonimmunized HPA‐1a‐negative women, 28 newborns had thrombocytopenia and 2 others had ICH. Conclusions: Feasibility of HPA‐1 antenatal screening was demonstrated, and a comprehensive biobank was established. The FNAIT detection rate was improved by retrospective diagnostics by PAKLx, including 3 newborns with ICH not identified by prospective MAIPA.
- 16 January 2026
- Published by Wiley in Transfusion
- Vol. 66 (4) , 814-827
HPA ‐1a alloimmunization and pregnancy outcome in a Polish screening program: PREVFNAIT
Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) caused by antibodies to human platelet antigen (HPA)‐1a in white HPA‐1a‐negative mothers is the most frequent cause of intracranial hemorrhage (ICH) in otherwise healthy newborns. Aims: To investigate the natural history of FNAIT and establish a biobank from HPA‐1a‐negative alloimmunized and nonimmunized pregnancies. Methods: A total of 24,259 pregnant women were recruited to the study during 2013–2017 and 24,236 were screened for HPA‐1a. Anti‐HPA‐1a antibodies were tested by Monoclonal Antibody Immobilization of Platelet Antigens (MAIPA) and some samples (MAIPA‐negative), with Luminex bead‐based immunoassay (PAKLx) if the neonate had thrombocytopenia and/or ICH. HPA‐1 genotyping of fathers, fetuses (from maternal plasma), and newborns was performed. Biological material was stored in biobanks in Norway and Poland. Results: Among 583/24,236 (2.4%) HPA‐1a‐negative women, samples were obtained from 529, of which 513 were examined during pregnancy. Anti‐HPA‐1a antibodies were detected in 48/529 (9.1%) women; whereof 34/513 (6.6%) during pregnancy, either by prospective MAIPA ( n = 27) or in retrospect by PAKLx in MAIPA‐negatives ( n = 7). FNAIT was diagnosed in 11/34 (32%) neonates from alloimmunized pregnancies: in 6/11 cases by prospective MAIPA and in 5/11 by retrospective PAKLx. There were no neonates with FNAIT‐associated ICH delivered by MAIPA‐positive women, but 3 ICH/severe thrombocytopenia cases were diagnosed by PAKLx. Among nonimmunized HPA‐1a‐negative women, 28 newborns had thrombocytopenia and 2 others had ICH. Conclusions: Feasibility of HPA‐1 antenatal screening was demonstrated, and a comprehensive biobank was established. The FNAIT detection rate was improved by retrospective diagnostics by PAKLx, including 3 newborns with ICH not identified by prospective MAIPA.
- 23 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1703-1708
Anti‐HNA testing of allo‐exposed COVID‐19 convalescent plasma donors including genetic human neutrophil antigen screening to prevent anti‐HNA antibody‐mediated transfusion‐related acute lung injury
Background: Transfusion‐related acute lung injury caused by antibodies against human neutrophil antigens (HNA) is a serious but rare complication associated with blood transfusion. The presence of such antibodies is most probable in donors with a transfusion/pregnancy history. During the COVID‐19 pandemic period convalescent plasma (CP) containing neutralizing antibodies against SARS‐CoV‐2 was widely used for COVID‐19 patients as a therapy in the absence of any treatment. The aim of the study was to work out a simple diagnostic algorithm of anti‐HNA testing of allo‐exposed CP donors including genetic HNA screening.Materials and Methods: A total of 457 anti‐HLA‐negative allo‐exposed CP donors were genotyped for HNA‐1a/1b, HNA‐3a/3b, and HNA‐2, and only donors with homozygous HNA‐1a/1a; HNA‐3b/3b; or HNA‐2null genotypes were tested for anti‐HNA antibody using LabScreenMulti (One Lambda) and homozygous HNA‐1b/1b using the granulocyte immunofluorescence test (GIFT) but verified using LabScreenMulti.Results: Testing of 83 homozygous HNA‐3b/3b; HNA‐2null; or HNA‐1a/1a donors revealed anti‐HNA‐3a antibody in one case. Testing of 181 HNA‐1b/1b donors using GIFT gave 10 ambiguous results verified using LabScreenMulti which confirmed anti‐HNA‐1a antibody in one case. The frequency of FCGR3B*01 and *04 encoding HNA‐1a was 0.34; FCGR3B*02, *03, and *05 encoding HNA‐1b—0.66; SLC44A2*01 encoding HNA‐3a—0.80; and SLC44A2*02 encoding HNA‐3b—0.20. In 3.7% cases the HNA‐2null genotype was revealed.Discussion: Due to applying HNA genotyping as a primary test before anti‐HNA antibody testing the serological work was limited only to HNA‐homozygous donors revealing two anti‐HNA immunized donors. The distribution of HNA genotypes in the cohort was similar to other Caucasian populations.
- 23 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1703-1708
Anti‐HNA testing of allo‐exposed COVID‐19 convalescent plasma donors including genetic human neutrophil antigen screening to prevent anti‐HNA antibody‐mediated transfusion‐related acute lung injury
Background: Transfusion‐related acute lung injury caused by antibodies against human neutrophil antigens (HNA) is a serious but rare complication associated with blood transfusion. The presence of such antibodies is most probable in donors with a transfusion/pregnancy history. During the COVID‐19 pandemic period convalescent plasma (CP) containing neutralizing antibodies against SARS‐CoV‐2 was widely used for COVID‐19 patients as a therapy in the absence of any treatment. The aim of the study was to work out a simple diagnostic algorithm of anti‐HNA testing of allo‐exposed CP donors including genetic HNA screening.Materials and Methods: A total of 457 anti‐HLA‐negative allo‐exposed CP donors were genotyped for HNA‐1a/1b, HNA‐3a/3b, and HNA‐2, and only donors with homozygous HNA‐1a/1a; HNA‐3b/3b; or HNA‐2null genotypes were tested for anti‐HNA antibody using LabScreenMulti (One Lambda) and homozygous HNA‐1b/1b using the granulocyte immunofluorescence test (GIFT) but verified using LabScreenMulti.Results: Testing of 83 homozygous HNA‐3b/3b; HNA‐2null; or HNA‐1a/1a donors revealed anti‐HNA‐3a antibody in one case. Testing of 181 HNA‐1b/1b donors using GIFT gave 10 ambiguous results verified using LabScreenMulti which confirmed anti‐HNA‐1a antibody in one case. The frequency of FCGR3B*01 and *04 encoding HNA‐1a was 0.34; FCGR3B*02, *03, and *05 encoding HNA‐1b—0.66; SLC44A2*01 encoding HNA‐3a—0.80; and SLC44A2*02 encoding HNA‐3b—0.20. In 3.7% cases the HNA‐2null genotype was revealed.Discussion: Due to applying HNA genotyping as a primary test before anti‐HNA antibody testing the serological work was limited only to HNA‐homozygous donors revealing two anti‐HNA immunized donors. The distribution of HNA genotypes in the cohort was similar to other Caucasian populations.
- 3 February 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30247
A high prevalence of neutrophil‐specific antibodies in ELANE‐mutated severe congenital neutropenia
An assay for neutrophil‐specific antibodies is frequently used in the workup of chronic severe neutropenia and is suggestive of autoimmune, or sporadically alloimmune neutropenia, rather than severe congenital neutropenia (SCN). We analyzed a neutropenia consortium database for the outcomes of antibody testing initiated before receiving genetic diagnosis in Polish SCN cohort. Test results, performed in a single reference laboratory, were available for 14 patients with ELANE‐mutated SCN or cyclic neutropenia, and were frequently positive (36%). We note that the trigger for genetic studies in severe neutropenia should not be affected by antibody‐positivity and should be clinically driven.
- 3 February 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30247
A high prevalence of neutrophil‐specific antibodies in ELANE‐mutated severe congenital neutropenia
An assay for neutrophil‐specific antibodies is frequently used in the workup of chronic severe neutropenia and is suggestive of autoimmune, or sporadically alloimmune neutropenia, rather than severe congenital neutropenia (SCN). We analyzed a neutropenia consortium database for the outcomes of antibody testing initiated before receiving genetic diagnosis in Polish SCN cohort. Test results, performed in a single reference laboratory, were available for 14 patients with ELANE‐mutated SCN or cyclic neutropenia, and were frequently positive (36%). We note that the trigger for genetic studies in severe neutropenia should not be affected by antibody‐positivity and should be clinically driven.
- 6 August 2022
- Published by Wiley in Transfusion
- Vol. 62 (9) , E43-E44
A novel KEL c.1414‐1G>T allele in a polish patient with anti‐Ku antibody
- 6 August 2022
- Published by Wiley in Transfusion
- Vol. 62 (9) , E43-E44
A novel KEL c.1414‐1G>T allele in a polish patient with anti‐Ku antibody
- 22 February 2022
- Published by Wiley in Transfusion
- Vol. 62 (4) , 863-870
Noninvasive diagnostics of fetal KEL*01.01 allele from maternal plasma of immunized women using digital PCR protocols
Allo-antibodies produced by K-negative pregnant women against a fetal K antigen from the Kell blood group system may cause hemolytic disease of the fetus and newborn (HDFN). Predicting the fetal K antigen using noninvasive prenatal testing (NIPT) is important for decisions concerning management of pregnancies. Digital and droplet digital PCR techniques permit the detection of fetal single nucleotide variant with a higher specificity and sensitivity than real-time polymerase chain reaction (PCR). Aim The aim was to evaluate and compare protocols for fetal KEL*01.01 genotyping using different assays and digital PCR platforms. Methods DNA isolated from 59 pregnant women (9–39 weeks of gestation, 49 with anti-K) was tested using home-made and custom-ordered KEL*01.01/KEL*02 assays with Droplet Digital™ and QuantStudio™3D. The results were compared with fetal/neonatal genotypes/phenotypes. Results Fetal KEL*01.01 results using all tested protocols were concordant with fetal/neonatal KEL*01.01 genotypes/phenotypes. None of the tested combinations of assays or digital PCR platforms gave false KEL*01.01-negative results, but inconclusive KEL*01.01 reads were observed in all tested protocols. For 36 cases compared using two digital PCR platforms and assays, there were not statistically significant differences in a level of fetal KEL*01.01 fraction (p < .72). Conclusion Independent of the applied dPCR and ddPCR platforms and KEL*01.01 assays, prediction of the fetal KEL*01.01 is highly reliable. Before implementation in routine practice further validation of the KEL*01.01 protocol with a larger group of pregnant women should be performed.
- 22 February 2022
- Published by Wiley in Transfusion
- Vol. 62 (4) , 863-870
Noninvasive diagnostics of fetal KEL*01.01 allele from maternal plasma of immunized women using digital PCR protocols
Allo-antibodies produced by K-negative pregnant women against a fetal K antigen from the Kell blood group system may cause hemolytic disease of the fetus and newborn (HDFN). Predicting the fetal K antigen using noninvasive prenatal testing (NIPT) is important for decisions concerning management of pregnancies. Digital and droplet digital PCR techniques permit the detection of fetal single nucleotide variant with a higher specificity and sensitivity than real-time polymerase chain reaction (PCR). Aim The aim was to evaluate and compare protocols for fetal KEL*01.01 genotyping using different assays and digital PCR platforms. Methods DNA isolated from 59 pregnant women (9–39 weeks of gestation, 49 with anti-K) was tested using home-made and custom-ordered KEL*01.01/KEL*02 assays with Droplet Digital™ and QuantStudio™3D. The results were compared with fetal/neonatal genotypes/phenotypes. Results Fetal KEL*01.01 results using all tested protocols were concordant with fetal/neonatal KEL*01.01 genotypes/phenotypes. None of the tested combinations of assays or digital PCR platforms gave false KEL*01.01-negative results, but inconclusive KEL*01.01 reads were observed in all tested protocols. For 36 cases compared using two digital PCR platforms and assays, there were not statistically significant differences in a level of fetal KEL*01.01 fraction (p < .72). Conclusion Independent of the applied dPCR and ddPCR platforms and KEL*01.01 assays, prediction of the fetal KEL*01.01 is highly reliable. Before implementation in routine practice further validation of the KEL*01.01 protocol with a larger group of pregnant women should be performed.
- 8 January 2022
- Published by Wiley in Transfusion
- Vol. 62 (2) , 458-468
Prediction of fetal blood group antigens from maternal plasma using Ion AmpliSeq HD technology
Background: Fetal blood group (BG) and platelet (HPA) antigens may trigger maternal immunization, causing a fetal disease. Noninvasive prenatal diagnostics (NIPT) predicts fetal genotype, identifying pregnancies with no risk. All current techniques detect fetal antigen alleles with unspecific background and without estimation of fetal fraction, thus new protocols for detection of fetal BG/HPA alleles with ultrahigh sensitivity still need to be tested to improve NIPT.Aim: To design NIPT of clinically important antigens using Ion AmpliSeq HD technology.Methods: Plasma DNA from 36 pregnant women (9–33 week of gestation, 24 immunized with anti‐HPA‐1a,‐3b,‐15a, ‐K, or ‐D+C+S), with known BG/HPA genotypes of their neonates/partners, was tested on Ion S5 System using the Ion AmpliSeq HD designer custom gene panel. NGS contained 25 rs‐targets encoding relevant BG/HPA antigens and 10 markers.Results: Using the NGS protocol, 76 out of 85 differences in fetal/maternal BG/HPA genotypes were determined in concentration above 2% fetal paternally inherited allele chimerism. The level of unspecific reads for BG/HPA alleles was below 0.87%. In 24 immunized women NGS revealed feto‐maternal incompatibility in 11 cases (from 2.44% to 7.41%) and excluded in 10 (<0.05%), three cases had inconclusive results (1.79%, 0.19%, 0.11%). The presence of fetal DNA was confirmed in each case by detecting markers with at least 2% chimerism.Conclusion: The use of Ion AmpliSeq HD technology improves the prediction of feto‐maternal incompatibility, increasing the sensitivity of BG/HPA NIPT and serving confirmation of the fetal DNA at the same workflow.
- 8 January 2022
- Published by Wiley in Transfusion
- Vol. 62 (2) , 458-468
Prediction of fetal blood group antigens from maternal plasma using Ion AmpliSeq HD technology
Background: Fetal blood group (BG) and platelet (HPA) antigens may trigger maternal immunization, causing a fetal disease. Noninvasive prenatal diagnostics (NIPT) predicts fetal genotype, identifying pregnancies with no risk. All current techniques detect fetal antigen alleles with unspecific background and without estimation of fetal fraction, thus new protocols for detection of fetal BG/HPA alleles with ultrahigh sensitivity still need to be tested to improve NIPT.Aim: To design NIPT of clinically important antigens using Ion AmpliSeq HD technology.Methods: Plasma DNA from 36 pregnant women (9–33 week of gestation, 24 immunized with anti‐HPA‐1a,‐3b,‐15a, ‐K, or ‐D+C+S), with known BG/HPA genotypes of their neonates/partners, was tested on Ion S5 System using the Ion AmpliSeq HD designer custom gene panel. NGS contained 25 rs‐targets encoding relevant BG/HPA antigens and 10 markers.Results: Using the NGS protocol, 76 out of 85 differences in fetal/maternal BG/HPA genotypes were determined in concentration above 2% fetal paternally inherited allele chimerism. The level of unspecific reads for BG/HPA alleles was below 0.87%. In 24 immunized women NGS revealed feto‐maternal incompatibility in 11 cases (from 2.44% to 7.41%) and excluded in 10 (<0.05%), three cases had inconclusive results (1.79%, 0.19%, 0.11%). The presence of fetal DNA was confirmed in each case by detecting markers with at least 2% chimerism.Conclusion: The use of Ion AmpliSeq HD technology improves the prediction of feto‐maternal incompatibility, increasing the sensitivity of BG/HPA NIPT and serving confirmation of the fetal DNA at the same workflow.
- 18 September 2020
- Published by Wiley in Transfusion
- Vol. 60 (11) , E48-E50
A novel ABO*A allele with 21 base pair duplication in Polish individuals
- 18 September 2020
- Published by Wiley in Transfusion
- Vol. 60 (11) , E48-E50
A novel ABO*A allele with 21 base pair duplication in Polish individuals
- Open Access
- 31 December 2019
- Published by VM Media Group sp. z o.o in Journal of Transfusion Medicine
- Vol. 12 (4) , 199-205
Molecular biology methods for blood cell antigen genotyping in reference laboratories
The aim of the study is to present current applications of molecular biology methods in immunohematology as well as the status of their implementation in the Polish Blood Transfusion Service. Molecular biology methods are used for: analysis of molecular background of blood cell antigens in individuals with discrepant results of serological tests, identification of RhD antigen with weak expression undetectable by serological methods in blood donors, identification of weak D type antigen in recipients unsusceptible to alloimmunization. These methods are also used for noninvasive study of fetal genes in plasma samples of immunized pregnant women with serological incompatibilities and in RhD negative pregnant women for qualification to antenatal prophylactic administration of anti-D immunoglobulin. Molecular biology is also an important tool for diagnostics of patients with antibodies to high-frequency blood group antigens (HFA) or for patients immunized with HPA and HNA antigens and for identification of “antigen-negative” blood donors for such patients. In Poland, all these tests are available and in use. The aim of the study is to present current applications of molecular biology methods in immunohematology as well as the status of their implementation in the Polish Blood Transfusion Service. Molecular biology methods are used for: analysis of molecular background of blood cell antigens in individuals with discrepant results of serological tests, identification of RhD antigen with weak expression undetectable by serological methods in blood donors, identification of weak D type antigen in recipients unsusceptible to alloimmunization. These methods are also used for noninvasive study of fetal genes in plasma samples of immunized pregnant women with serological incompatibilities and in RhD negative pregnant women for qualification to antenatal prophylactic administration of anti-D immunoglobulin. Molecular biology is also an important tool for diagnostics of patients with antibodies to high-frequency blood group antigens (HFA) or for patients immunized with HPA and HNA antigens and for identification of “antigen-negative” blood donors for such patients. In Poland, all these tests are available and in use.
- 31 December 2019
- Published by VM Media Group sp. z o.o in Journal of Transfusion Medicine
- Vol. 12 (4) , 199-205
Open AccessMolecular biology methods for blood cell antigen genotyping in reference laboratories
The aim of the study is to present current applications of molecular biology methods in immunohematology as well as the status of their implementation in the Polish Blood Transfusion Service. Molecular biology methods are used for: analysis of molecular background of blood cell antigens in individuals with discrepant results of serological tests, identification of RhD antigen with weak expression undetectable by serological methods in blood donors, identification of weak D type antigen in recipients unsusceptible to alloimmunization. These methods are also used for noninvasive study of fetal genes in plasma samples of immunized pregnant women with serological incompatibilities and in RhD negative pregnant women for qualification to antenatal prophylactic administration of anti-D immunoglobulin. Molecular biology is also an important tool for diagnostics of patients with antibodies to high-frequency blood group antigens (HFA) or for patients immunized with HPA and HNA antigens and for identification of “antigen-negative” blood donors for such patients. In Poland, all these tests are available and in use. The aim of the study is to present current applications of molecular biology methods in immunohematology as well as the status of their implementation in the Polish Blood Transfusion Service. Molecular biology methods are used for: analysis of molecular background of blood cell antigens in individuals with discrepant results of serological tests, identification of RhD antigen with weak expression undetectable by serological methods in blood donors, identification of weak D type antigen in recipients unsusceptible to alloimmunization. These methods are also used for noninvasive study of fetal genes in plasma samples of immunized pregnant women with serological incompatibilities and in RhD negative pregnant women for qualification to antenatal prophylactic administration of anti-D immunoglobulin. Molecular biology is also an important tool for diagnostics of patients with antibodies to high-frequency blood group antigens (HFA) or for patients immunized with HPA and HNA antigens and for identification of “antigen-negative” blood donors for such patients. In Poland, all these tests are available and in use.
- Open Access
- 6 September 2019
- Published by VM Media Group sp. z o.o in Journal of Transfusion Medicine
- Vol. 12 (2) , 56-64
Rozwój technologii opartych na metodach biologii molekularnej do oznaczania grup krwi
- 6 September 2019
- Published by VM Media Group sp. z o.o in Journal of Transfusion Medicine
- Vol. 12 (2) , 56-64
Open AccessRozwój technologii opartych na metodach biologii molekularnej do oznaczania grup krwi
- Open Access
- 1 September 2019
- Published by Taylor & Francis in International Journal of Clinical Transfusion Medicine
- Vol. ume 7, 11-22
Potential of next-generation sequencing to match blood group antigens for transfusion
A review of the advances in applying next-generation sequencing (NGS) to transfusion medicine for the purpose of genotyping alleles encoding clinically important red blood cell and platelet antigens. NGS data from published studies confirm the possibility of antigen prediction based on sequencing of the whole genome, exome or targeted regions. What remains a challenge, to provide highly accurate NGS genotyping, is the further improvement of bioinformatic solutions for automated interpretation based on publicly accessible and improved reference databases appropriate for NGS methods as well as validation of a method based on the examination of a large number of individuals. There is no doubt, however, as to the future of NGS as a supplementary test used to provide highly compatible blood as well as to reduce the risk of patient’s alloimmunization. This is part of personalized medicine.
- 1 September 2019
- Published by Taylor & Francis in International Journal of Clinical Transfusion Medicine
- Vol. ume 7, 11-22
Open AccessPotential of next-generation sequencing to match blood group antigens for transfusion
A review of the advances in applying next-generation sequencing (NGS) to transfusion medicine for the purpose of genotyping alleles encoding clinically important red blood cell and platelet antigens. NGS data from published studies confirm the possibility of antigen prediction based on sequencing of the whole genome, exome or targeted regions. What remains a challenge, to provide highly accurate NGS genotyping, is the further improvement of bioinformatic solutions for automated interpretation based on publicly accessible and improved reference databases appropriate for NGS methods as well as validation of a method based on the examination of a large number of individuals. There is no doubt, however, as to the future of NGS as a supplementary test used to provide highly compatible blood as well as to reduce the risk of patient’s alloimmunization. This is part of personalized medicine.